- Home
- RBNE vs IMNN Comparison
RBNE vs IMNN Comparison
Compare RBNE & IMNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RBNE | IMNN |
|---|---|---|
| Founded | 2024 | 1982 |
| Country | Cyprus | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.5M | 12.5M |
| IPO Year | N/A | 1985 |
Fundamental Metrics
Financial Performance| Metric | RBNE | IMNN |
|---|---|---|
| Price | $4.01 | $3.40 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $182.61 |
| AVG Volume (30 Days) | ★ 302.3K | 36.3K |
| Earning Date | 04-17-2026 | 03-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.09 | N/A |
| Revenue | ★ $6,869,234.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $45.39 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.78 | $2.99 |
| 52 Week High | $123.25 | $41.22 |
Technical Indicators
Market Signals| Indicator | RBNE | IMNN |
|---|---|---|
| Relative Strength Index (RSI) | 51.16 | 48.17 |
| Support Level | $3.67 | $3.25 |
| Resistance Level | $4.47 | $3.62 |
| Average True Range (ATR) | 0.57 | 0.23 |
| MACD | -0.13 | 0.02 |
| Stochastic Oscillator | 21.87 | 42.53 |
Price Performance
Historical ComparisonAbout RBNE Robin Energy Ltd.
Robin Energy Ltd operates a tanker vessel that engages in the transportation of refined petroleum products using its Handysize product tanker.
About IMNN Imunon Inc.
Imunon Inc is a clinical-stage biotechnology company focused on advancing a portfolio of treatments that harness the body's natural mechanisms to generate safe, effective, and durable responses across various human diseases, constituting a differentiating approach from conventional therapies. It is developing its non-viral DNA technology across its modalities. Its clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of ovarian cancer that has completed Phase II clinical studies. Additionally, the Company has entered a first-in-human study of its COVID-19 booster vaccine (IMNN-101).